Key result
TriClip TEER reduces TR to moderate or less in ~87% of patients, improving QoL.
Why the study?
Severe tricuspid regurgitation carries significant morbidity and mortality, but classical surgery has high postprocedural mortality, motivating transcatheter intervention reviews.
This review highlights that transcatheter edge-to-edge repair with the TriClip device is a safe and effective alternative to surgery for reducing severe tricuspid regurgitation and improving quality of life.
May support TriClip consideration in severe TR; leaves open need for randomized trials before practice change.
Severe tricuspid regurgitation (TR) is a common pathology in the daily practice of a cardiologist. This disease entity is associated with significant morbidity and mortality if left untreated. Classically, surgical repair or replacement were the only therapeutic options present and were often not performed due to high postprocedural mortality. Transcatheter tricuspid valve intervention has emerged as a novel and effective therapeutic option for the treatment of significant TR. Several devices have been developed with different mechanisms of action. In this review, we will provide an overview of transcatheter edge-to-edge repair of TR using the TriClip device (Abbott, Santa Clara, CA, USA).
No takes yet. Share an insight, caveat, or question.
Matli et al. (2024) conducted a review in Tricuspid Regurgitation. TriClip (transcatheter edge-to-edge repair) was evaluated. Transcatheter edge-to-edge repair with TriClip reduces tricuspid regurgitation to moderate or less severity in 87% of patients and significantly improves quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: